Community Consensus
Community Consensus
Reader sentiment on the compounds this article compares. Votes count toward each compound's own tally.
- Urolithin A2k votes · 86%👍
Reader sentiment only. Not medical advice, not a recommendation, and not a measure of evidence quality.
Quick answer
Urolithin A has a clean safety profile in human research. Clinical trials, including the first-in-human safety study, found it well tolerated with side effects that were mild, infrequent, and often similar to placebo. When they occur, side effects are usually minor digestive issues like bloating or nausea. Pregnant or breastfeeding people, and anyone on medication, should consult a clinician first.
Key takeaways
- Human trials, including a first-in-human safety study, found urolithin A safe and well tolerated.
- It's a postbiotic your gut already makes from pomegranates and walnuts, so it's biologically familiar.
- When side effects occur they are typically mild and digestive (bloating, gas, occasional nausea).
- In trials, side effects were often similar to placebo.
- Pregnant/breastfeeding people and those on medication should get medical guidance first.
The short answer
Urolithin A has a reassuringly clean safety profile in the human research so far. Clinical trials, including the first-in-human safety study, found it well tolerated, with side effects that were mild, infrequent, and comparable to placebo. It’s a compound your own gut bacteria already make from foods like pomegranates and walnuts, which is part of why the body treats it as familiar.
What the research shows on safety
The landmark first-in-human trial was built specifically to evaluate safety, and it found urolithin A safe and well tolerated across the doses studied. Later randomized trials in older and middle-aged adults reported no significant safety concerns. For a supplement, that’s a stronger dataset than most can point to. (Background in the full Urolithin A guide.)
Possible side effects
When side effects do show up, they’re usually mild and digestive, the usual suspects for any oral supplement:
- Mild digestive upset: occasional bloating, gas, or stomach discomfort, especially at higher doses.
- Nausea: uncommon, and usually mild when it happens.
- In trials, reported side effects were generally similar to placebo, meaning they weren’t clearly attributable to urolithin A itself.
Taking it with food can help minimize any digestive discomfort.
Who should be cautious
Even with a clean profile, a few groups should get medical guidance first:
- Pregnant or breastfeeding: there isn’t enough data, so the default is to avoid.
- People on medications or with health conditions: as with any supplement, check for interactions.
- Anyone starting a new supplement: begin at a standard dose rather than megadosing.
Long-term safety
Human trials have run for several months without notable safety signals, which is encouraging. As with most newer supplements, very-long-term (multi-year) data is still accumulating. That’s a reasonable caveat, not a red flag.
Doses used in the studies
The trials behind this safety profile mostly tested 500 mg to 1,000 mg per day, taken as a single daily dose. Side effects did not scale up meaningfully at the higher end of that range, which is part of why the data reads as reassuring rather than dose-dependent. When digestive discomfort does show up, it typically eases within the first week or two as the body adjusts. Starting at a lower dose before moving to a full dose is a reasonable approach if you tend to be sensitive to new supplements generally.
Who should be cautious, at a glance
| Group | Guidance |
|---|---|
| Pregnant or breastfeeding | Avoid; insufficient safety data for this group |
| On medication or managing a health condition | Check for interactions with a clinician before starting |
| New to supplements generally | Start at a standard dose rather than the higher end of the studied range |
| Everyone else | Generally well tolerated at studied doses, per the trial data above |
Bottom line
Urolithin A is among the better-tolerated supplements in the mitochondrial space, with side effects that are mild, uncommon, and often indistinguishable from placebo. Take it with food, stick to standard doses, and if you’re pregnant, breastfeeding, or on medication, clear it with a clinician first.
Educational information only, not medical advice. Consult a clinician if you’re pregnant, breastfeeding, taking medication, or managing a health condition.
Frequently asked questions
Does urolithin A have side effects?
In human trials, urolithin A was well tolerated, and reported side effects were mild, infrequent, and often similar to placebo. When they occur, they're usually minor digestive issues such as bloating, gas, or occasional nausea. Taking it with food can help.
Is urolithin A safe?
The human research to date is reassuring: the first-in-human safety trial and later randomized studies found it safe and well tolerated with no significant safety concerns. It's among the better-tolerated supplements in the mitochondrial space.
Who should not take urolithin A?
Pregnant or breastfeeding people should avoid it due to insufficient data. Anyone on medication or managing a health condition should check with a clinician for interactions before starting. Otherwise, standard doses are generally well tolerated.
Is urolithin A safe long-term?
Human trials lasting several months have shown no notable safety signals, which is encouraging. As with most newer supplements, multi-year data is still accumulating, a reasonable caveat rather than a red flag.
References
- 1.Andreux PA, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nat Metab. 2019;1:595-603.
- 2.Liu S, et al. Effect of urolithin A supplementation on muscle endurance and mitochondrial health in older adults: a randomized clinical trial. JAMA Netw Open. 2022;5(1):e2144279.
- 3.Singh A, et al. Direct supplementation with Urolithin A overcomes limitations of dietary exposure and gut microbiome variability. Eur J Clin Nutr. 2022;76(2):297-308.